GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Huadong Medicine Co Ltd (SZSE:000963) » Definitions » Equity-to-Asset
中文

Huadong Medicine Co (SZSE:000963) Equity-to-Asset : 0.63 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Huadong Medicine Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Huadong Medicine Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ¥21,048 Mil. Huadong Medicine Co's Total Assets for the quarter that ended in Dec. 2023 was ¥33,509 Mil. Therefore, Huadong Medicine Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.63.

The historical rank and industry rank for Huadong Medicine Co's Equity-to-Asset or its related term are showing as below:

SZSE:000963' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25   Med: 0.55   Max: 0.63
Current: 0.63

During the past 13 years, the highest Equity to Asset Ratio of Huadong Medicine Co was 0.63. The lowest was 0.25. And the median was 0.55.

SZSE:000963's Equity-to-Asset is ranked better than
57.13% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs SZSE:000963: 0.63

Huadong Medicine Co Equity-to-Asset Historical Data

The historical data trend for Huadong Medicine Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Huadong Medicine Co Equity-to-Asset Chart

Huadong Medicine Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.60 0.61 0.60 0.63

Huadong Medicine Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.60 0.60 0.59 0.60 0.63

Competitive Comparison of Huadong Medicine Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Huadong Medicine Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Huadong Medicine Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Huadong Medicine Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Huadong Medicine Co's Equity-to-Asset falls into.



Huadong Medicine Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Huadong Medicine Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=21047.61/33509.362
=0.63

Huadong Medicine Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=21047.61/33509.362
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Huadong Medicine Co  (SZSE:000963) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Huadong Medicine Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Huadong Medicine Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Huadong Medicine Co (SZSE:000963) Business Description

Traded in Other Exchanges
N/A
Address
468 Yan’an Road, Floor 7, 9 and 10, Gate No. 1, Building No. 1, Hangzhou, CHN, 310006
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.

Huadong Medicine Co (SZSE:000963) Headlines

No Headlines